共 50 条
Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study
被引:19
|作者:
Brzostek, Dorota
[1
]
Kokot, Marek
[1
]
机构:
[1] Takeda Poland, PL-02305 Warsaw, Poland
来源:
POSTEPY DERMATOLOGII I ALERGOLOGII
|
2014年
/
31卷
/
06期
关键词:
asthma;
chronic obstructive pulmonary disease;
asthma-chronic obstructive pulmonary disease overlap syndrome;
concomitant diseases;
phenotype;
COPD;
FEATURES;
HEALTH;
D O I:
10.5114/pdia.2014.47120
中图分类号:
R392 [医学免疫学];
学科分类号:
100102 ;
摘要:
Introduction: Recent years have seen an increased interest in asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS). Aim: In 2012, Takeda Polska conducted a non-interventional epidemiological study aimed at identifying the typical phenotype of ACOS patients receiving pulmonary care. Material and methods: The study enrolled a total of 12,103 of smoking patients above 45 years of age (mean age: 61.5 years; mean duration of smoking: 28.4 pack-years). A total of 68.6% of patients represented the frequent-exacerbation phenotype (mean number of exacerbations during 12 months: 2.11), and 56.4% of patients from the group comprising 12,103 participants were hospitalized at least once during their lifetime due to a respiratory system disease (mean number: 3.82 +/- 3.76). Results: The most commonly found asthma symptoms included paroxysmal dyspnoea with wheezing, and good response to inhaled steroids. The most frequently identified COPD-associated symptoms were: long-lasting reduction in forced expiratory volume in 1 s (FEV1) (< 80% after administering a bronchodilator) and chronic productive cough. Eighty-five percent of patients were diagnosed with concomitant diseases, predominantly arterial hypertension (62.9%) and metabolic diseases (metabolic syndrome, obesity, type 2 diabetes - 46.4% in total). Conclusions: A clinically severe course of ACOS and the presence of concomitant diseases should be regarded as factors justifying an individual selection of inhalation therapy which specifically takes into account anti-inflammatory treatment and patient safety.
引用
收藏
页码:372 / 379
页数:8
相关论文